FDA and European Union fail to reach agreement on good manufacturing practices (GMP):
This article was originally published in Clinica
Executive Summary
US FDA and European Union officials meeting in Brussels early this month made no progress in their efforts to harmonise Good Manufacturing Practices and final marketing decisions for medical devices. A meeting last November also ended in a stalemate. US representatives distributed a paper at the June session that "clarified and refined" the agency's earlier position, a source says, although it failed to impress the Europeans. American bureaucrats say they feel it would be "premature" to move ahead on mutual recognition agreements until a planned pilot programme of third-party review has been completed and assessed. Nevertheless, delegates issued a joint paper and agreed to continue discussions.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.